JP2019508181A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508181A5
JP2019508181A5 JP2018548884A JP2018548884A JP2019508181A5 JP 2019508181 A5 JP2019508181 A5 JP 2019508181A5 JP 2018548884 A JP2018548884 A JP 2018548884A JP 2018548884 A JP2018548884 A JP 2018548884A JP 2019508181 A5 JP2019508181 A5 JP 2019508181A5
Authority
JP
Japan
Prior art keywords
solution
self
cerebrospinal fluid
leakage
assembling peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018548884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508181A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/000387 external-priority patent/WO2017158435A1/en
Publication of JP2019508181A publication Critical patent/JP2019508181A/ja
Publication of JP2019508181A5 publication Critical patent/JP2019508181A5/ja
Pending legal-status Critical Current

Links

JP2018548884A 2016-03-18 2017-03-17 脳脊髄液の漏出の閉鎖 Pending JP2019508181A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662310122P 2016-03-18 2016-03-18
US62/310,122 2016-03-18
PCT/IB2017/000387 WO2017158435A1 (en) 2016-03-18 2017-03-17 Cerebrospinal fluid leakage occlusion

Publications (2)

Publication Number Publication Date
JP2019508181A JP2019508181A (ja) 2019-03-28
JP2019508181A5 true JP2019508181A5 (cg-RX-API-DMAC7.html) 2020-04-23

Family

ID=58645333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548884A Pending JP2019508181A (ja) 2016-03-18 2017-03-17 脳脊髄液の漏出の閉鎖

Country Status (9)

Country Link
US (1) US20210023257A1 (cg-RX-API-DMAC7.html)
EP (1) EP3429645A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019508181A (cg-RX-API-DMAC7.html)
CN (1) CN109195640A (cg-RX-API-DMAC7.html)
AU (1) AU2017232550A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018068939A2 (cg-RX-API-DMAC7.html)
CL (1) CL2018002643A1 (cg-RX-API-DMAC7.html)
MX (1) MX2018011201A (cg-RX-API-DMAC7.html)
WO (1) WO2017158435A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018011121A (es) 2016-03-18 2019-01-31 3 D Matrix Ltd Prevención de la adherencia de tejido biológico.
WO2021202577A1 (en) 2020-03-31 2021-10-07 3-D Matrix, Ltd. Sterilization of self-assembling peptides by irradiation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9162005B2 (en) * 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
EP2283851B1 (en) * 2005-04-25 2023-06-07 Massachusetts Institute of Technology Compositions for promoting hemostasis
US7854923B2 (en) * 2006-04-18 2010-12-21 Endomedix, Inc. Biopolymer system for tissue sealing
HUE037994T2 (hu) * 2006-04-25 2018-09-28 Massachusetts Inst Technology Készítmények és eljárások szennyezõ anyagok, testfolyadékok vagy más anyagok mozgásának befolyásolására és/vagy más fiziológiai állapotok befolyásolására
RU2011118341A (ru) * 2008-10-06 2012-11-20 3-Д Матрикс, Лтд. (Jp) Агент для окклюзии тканей
CN103800941B (zh) * 2012-11-09 2015-04-22 北京银河巴马生物技术股份有限公司 一种i型胶原材料、脑膜或脊膜生物膜片及其制备方法和应用
US20160287744A1 (en) * 2012-11-14 2016-10-06 3-D Matrix Ltd. Vascular embolic system
WO2014141160A1 (en) * 2013-03-14 2014-09-18 3-D Matrix, Ltd Treatment for bile leakage

Similar Documents

Publication Publication Date Title
Vigani et al. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes
JP2019508175A5 (cg-RX-API-DMAC7.html)
US20210031012A1 (en) Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
JP2014221830A5 (cg-RX-API-DMAC7.html)
US11419954B2 (en) Targeted protein contrast agents, methods of making, and uses thereof
JP2020509048A5 (cg-RX-API-DMAC7.html)
WO2020097511A3 (en) Messenger rna therapy for treatment of ocular diseases
JP2018512454A5 (cg-RX-API-DMAC7.html)
JP2016539921A5 (cg-RX-API-DMAC7.html)
AU2017339970A1 (en) Compounds and methods for activating Tie2 signaling
US20230041197A1 (en) Treatment of a disease of the gastrointestinal tract with an immunomodulator
JP2016513523A5 (cg-RX-API-DMAC7.html)
JP2019508181A5 (cg-RX-API-DMAC7.html)
CA2514584A1 (en) Peptide inhibitors of toxins derived from ll-37
Shi et al. Advances in nanotherapy for targeting senescent cells
Sun et al. Emerging nanotherapeutic strategies targeting gut-X axis against diseases
JP2021502337A5 (cg-RX-API-DMAC7.html)
JP2018527345A (ja) ポリマーおよびその使用方法
Shunmugaperumal et al. Multifunctional nanosized emulsions for theragnosis of life threatening diseases
CN108273038B (zh) 防治肠型放射病的药物组合物
MX2018011201A (es) Oclusion de fuga de liquido cefalorraquideo.
US10695399B2 (en) Peptides for prevention of HIV infection
Maduka et al. Engineering nanoparticles that target fibroblast activation protein in cardiac fibrosis
RU2015133365A (ru) Альфа-2 адренергический агонист для лечения внутриглазного давления и заболеваний глаз путем введения в стекловидное тело и внутрикамерно
RU2022102195A (ru) Новые способы лечения бокового амиотрофического склероза